Cannabiz: The long and winding road to S3 registration
Avecho is headlining respected news website, Cannabiz, this morning in an article titled, ‘The long and winding road to S3 registration’.
Here is an excerpt:
Unlike most companies looking to bring a low-dose CBD product to market, Avecho’s roots lay outside the world of medicinal cannabis.
It emerged as a medicine of interest after Avecho identified it as an ideal fit for TPM®, Gavin said.
“If you were to describe the attributes of a drug that would most perfectly fit our technology, it would be a lipid soluable drug with poor bioavailabilty and no data. That essentially describes medicinal cannabis.
“We’re real biotech, and only dipped our toe in the water 18 months ago (with medicinal cannabis) because we understand drug development and we understand clinical trials. These seemed to be things lacking in medicinal cannabis. And our technology looked particularly suitable to cannabinoids.
“It’s got really poor absorption. Patients are paying for a drug 90% [of which] they won’t use because they’ll either excrete it or metabolise it. That’s where we think we can add value, by increasing that absorption.
“The way we have built our formulations is that you could plug and play any cannabinoid into the formulation and it should work just as well, whether it’s natural or synthetic and whether it’s CBD or THC.”